The p53/MDM2/MDMX-targeted therapies-a clinical synopsis

Cell Death Dis. 2020 Apr 17;11(4):237. doi: 10.1038/s41419-020-2445-9.

Authors

Liren Jiang¹, Joanna Zawacka-Pankau^{2

3}

Affiliations

¹ Department of Pathology Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai, 200080, China.
² Department of Oncology-Pathology, Karolinska Institute, Stockholm, SE-171 64, Sweden. j.zawackapan@uw.edu.pl.
³ Faculty of Chemistry, University of Warsaw, 02-093, Warsaw, Poland. j.zawackapan@uw.edu.pl.

No abstract available

MeSH terms

Humans
Proto-Oncogene Proteins c-mdm2 / pharmacology
Proto-Oncogene Proteins c-mdm2 / therapeutic use*
Tumor Suppressor Protein p53 / metabolism*

Substances

Tumor Suppressor Protein p53
MDM2 protein, human
Proto-Oncogene Proteins c-mdm2